The University of Bari Aldo Moro presented data from an in vivo study assessing the effects of irisin on pancreatic islets of diabetic mice (type 2 diabetes).

Autosomal dominant hypocalcemia (ADH) type 1 and 2 are disorders that affect calcium homeostasis caused by gain-of-function mutations in CaSR, which encodes the calcium-sensing receptor.

Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.

A simple injection of muscle tissue could control glucose in patients with type 2 diabetes (T2D). Genetic modification of skeletal muscle and subsequent intramuscular implantation could increase blood sugar absorption and become an effective and long-lasting treatment for this pathology. “We took mice satellite cells and we genetically altered to overexpress GLUT4,” Hagit Shoyhet, researcher at the Levenberg lab of stem-cell and tissue engineering, Technion (Israel), said at the European Association for the study of Diabetes (EASD) 58th Annual Meeting.

A series of novel tacrine derivatives acting as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor subtype antagonists has been developed in research seeking to exploit these targets for the treatment of Alzheimer's disease.

Researchers from the U.K. have investigated the specificity and sensitivity of clonidine growth hormone (GH) as a biomarker for the differential diagnosis of multiple system atrophy (MSA) from pure autonomic failure (PAF), Parkinson’s disease (PD) and progressive supranuclear palsy (PSP).

Researchers from Tyra Biosciences Inc. presented a novel FGFR3-selective inhibitor agnostic to the gatekeeper mutation, named TYRA-300.

Researchers from the University of Santiago de Compostela and University of Porto have reported the discovery of a novel acetylcholinesterase (AChE) inhibitor, MJM-255.